November 15, 2026
$RichWire Markets and money, explained simply
LIVE
Gold Faces Downward Pressure as Strong Inflation Data Strengthens the Dollar Nuclear SMR Developer X-Energy Goes Public at $23 per Share Accelevation Reaffirms 2026 Guidance in First Earnings Call Following Public Debut Bitcoin Risks Further Fall Toward $40,000 as Analyst Warns of December Capitulation Building a $600,000 Dividend Portfolio With Systematic ETF Investing Pinterest Valuation Faces Pressure as Growth Slows Amid AI Disruption Fears Honeywell Aerospace Posts $4.6 Billion in Third-Quarter Sales on Strong Commercial Demand Bitcoin Teeters Near $65,000 Support as ETF Outflows and Miner Stress Mount Gold Nears Key Support at 3850 as Analysts Weigh Recovery Potential GBP/JPY Faces Downward Pressure After Channel Breakdown Gold Tests Critical Support as Descending Trendline Pressure Persists Goldman Sachs BDC Faces Credit Quality Pressures and Lower Dividend Coverage Gold Faces Downward Pressure as Strong Inflation Data Strengthens the Dollar Nuclear SMR Developer X-Energy Goes Public at $23 per Share Accelevation Reaffirms 2026 Guidance in First Earnings Call Following Public Debut Bitcoin Risks Further Fall Toward $40,000 as Analyst Warns of December Capitulation Building a $600,000 Dividend Portfolio With Systematic ETF Investing Pinterest Valuation Faces Pressure as Growth Slows Amid AI Disruption Fears Honeywell Aerospace Posts $4.6 Billion in Third-Quarter Sales on Strong Commercial Demand Bitcoin Teeters Near $65,000 Support as ETF Outflows and Miner Stress Mount Gold Nears Key Support at 3850 as Analysts Weigh Recovery Potential GBP/JPY Faces Downward Pressure After Channel Breakdown Gold Tests Critical Support as Descending Trendline Pressure Persists Goldman Sachs BDC Faces Credit Quality Pressures and Lower Dividend Coverage

Technical Outlook: Liven Pharma Faces Key Resistance Level

🧠 AI Analysis 1 min read 👁 2

Liven Pharma shares show signs of a potential bullish reversal, though the stock must clear a critical resistance barrier to confirm further gains.

Technical Outlook: Liven Pharma Faces Key Resistance Level🧠AI Analysis

Photo: tradingview.com

Key points

  • Liven Pharma closed at 39.19 on November 13, 2026.
  • A double bottom formation suggests a potential bullish reversal.
  • Resistance is identified at 40.50–41.00, with support holding at 28.

Liven Pharma Ltd (LIVEN) shares closed at 39.19 on November 13, 2026, as technical indicators suggest a potential shift in momentum. Analysts have identified a double bottom formation accompanied by bullish divergence, a pattern often associated with a reversal of previous downward trends.

For investors monitoring the stock, the immediate focus is on the 40.50 to 41.00 price range. A sustained breakout above this resistance zone is considered necessary to validate the bullish outlook. Should the stock successfully clear this hurdle, technical targets of 50 and 55 could come into play.

On the downside, market participants are watching the 28 support level closely. Maintaining this floor is viewed as essential for preserving the integrity of the current technical setup. Failure to hold this support could invalidate the existing bullish formation.

What to watch next: Investors should monitor whether the stock can achieve a decisive close above 41.00 to confirm the upward trend.

Source tradingview.com — tradingview.com/chart/LIVEN/lTGIScH0-LIVEN-55-in-Sight-Bulls-Must-C… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.